The costs of radical prostatectomy and radiation therapy for localized carcinoma of the prostate are well known, the costs of terminal care for men with metastatic disease less so. We sought to determine the costs of terminal care incurred with prostate cancer in the last year of life. A retrospective chart review was conducted at five military medical centers identifying 32 patients who had died from prostate cancer from 1995 to 1997. The data investigated were: duration of metastatic disease, days hospitalized in the last year of life, palliative procedures (surgery or radiation), chemotherapy and need for transfusions. The mean duration of symptomatic metastatic disease was 3.4 y. The mean duration of hospitalization in the last year of life was 19 days. Seven patients (22%) required channel transurethral resection of the prostate (TURP). Three patients (9%) required either percutaneous nephrostomies or stenting. The mean number of transfusions required was 5.4. Eighteen patients (56%) underwent bilateral simple orchiectomy (BSO), 14 (44%) used LHRH agonists and 11 (34%) used antiandrogens. The mean total cost of hospitalization, studies, outpatient visits to physicians, palliative procedures and hormonal therapy was $24 660 in the last year of life. Comparatively, the cost of radical prostatectomy is $12 250 and threedimensional conformal radiation therapy is $13 823. Our estimation of costs due to metastatic disease is at best an underestimation. Men dying of prostate cancer incur significant costs in the last year of life. Based upon recent epidemiological data the cost of death due to prostate cancer in the US is over three quarters of a billion dollars a year.
Introduction
In 2001 there will be an estimated 198 100 new cases and 31 500 deaths due to prostate cancer. 1 Controversy exists regarding initial treatment of patients with localized disease vs observation with intent to treat if and when symptomatic metastases occur. Proponents of 'watchful waiting' feel that the intercurrent mortality rate in this population speaks to avoiding the overtreatment of a disease that may have a minimal short-term impact. Additionally, in an era of increasing concerns regarding the rising cost of health care, observation becomes attractive in comparison to radical first line therapy. Previously others have discussed the costs of screening for and treatment of localized disease. 2 We, however, sought to compare the costs incurred in the last year of life with metastatic prostate cancer and, admittedly, superficially compare these with those of aggressive treatment of localized disease. Our question is: If treatment is delayed until development of symptomatic metastases and the patient then succumbs would it have been more economical to treat initially?
Methods
From the Center for Prostate Disease Research Database, (a Department of Defense Multi-institutional database) 50 patients who died between 1995 and 1997 with a known diagnosis of prostate cancer, were identified irrespective of the cause of death. All types of hospital care and all relevant outpatient records regarding these patients were retrospectively analyzed for the last 12 months of life. Eighteen patients were excluded secondary to incomplete records, history of prior localized prostate cancer treatment, or death secondary to another cause. The duration of metastatic disease, and the number of days spent hospitalized were analyzed. Only the number of days hospitalized as a direct consequence of prostate cancer was registered. The number of palliative therapies or procedures to unobstruct the upper tract (such as pyelostomies, stent insertion) was registered. The number of transfusions required for each patient was tabulated. In addition, any other identifiable billable charges (medications, outpatient visits, inpatient consultations, laboratory and radiologic studies, etc.) were tabulated. Military medical centers primarily are cost free to their patients, so to determine the costs incurred by these patients, we utilized current procedural terminology (CPT) codes and billing charges from a local community hospital. This allowed a comparative assessment of what civilian patients would pay for similar care. Further, with the help of a local civilian pharmacy, medication charges were obtained.
Results
Mean patient age in the last year of life was 67 y (range 58 -81). The mean duration of symptomatic metastasis was 3.4 y, a range of 2.4 months to 8 y. The number of days hospitalized in the last year of life was an average of 19 with a maximum of 3 months. There were 45 palliative procedures, several patients undergoing multiple procedures; the types and costs are listed in Table 1 . These costs are minimum hospital charges for the procedure and do not include physician charges or additional laboratory or radiological studies that coincided with the procedure. Approximately half (50%) required some type of blood component; with an average of 14 blood products per patient that required transfusion (including packed red blood cells (PRBCs), platelets, etc.). One patient received 81 separate blood products. All patients received laboratory studies or X-rays in some form or another. The various types are listed in Table 2 with their attached costs.
Additional consultations were at times needed. These had various prices ranging from $93.00 for a radiological reading to $128.00 for a neurosurgical consultation. In addition, anesthesia costs for the surgical procedures listed were calculated with a base price of $3250.00, an amount possibly increased based upon the length of the procedure. A daily inpatient physician visit was $58.00 and the daily inpatient basic hospital charge was $395.00.
A list of the medication utilized by our patients is in Table 3 . The prices obtained are an average cost in the local area of San Antonio, Texas.
An attempt was made to assign a cost for every item, or test utilized, however some costs were unavailable based upon the records available. These include costs of Hospice, mental health care, home health care and other intangible costs, specifically, the household economic costs.
Placed in perspective, the cost of a radical prostatectomy is approximately $12 250, conformal radiation therapy $13 823 and brachytherapy $21 025. These costs were obtained from various recent literature reviews. 3 The total mean cost of treatment in the last year of life for a patient with metastatic prostate cancer in this series was $24 660 with a range of $8606 to $64 447.
Discussion
Critics of treatment of localized prostate cancer have argued that, depending on patient age or co-morbidities, treatment is not necessarily needed. The rationale of evaluating the last year of a patient's life was chosen because it is at that time that health care is sought most often. We propose that not only would treatment save money in the long run but also improve one's quality of life, especially in this last year. This report, obviously, does not prove this hypothesis. Proof or refutation thereof would require a long-term randomized study (currently underway in the Prostate Cancer Intervention Versus Observation Trial, or PIVOT). However, this study and 4 In a 1995 review, Otnes et al reported a mean hospital stay of one month. 5 This accounted for 6% of his patients duration of life from the time of diagnosis to death. The current study assesses an average of 19 days hospitalized in the last year with one patient spending almost 25% of his last year hospitalized
Carlsson et al, also using cost as a parameter, found that patients who died of prostate cancer had a three-fold greater health care expenditure compared to those who died of other causes. 6 He also noted that the survival time did not affect the total cost. This is felt to be secondary to the fact that most palliative, and expensive, procedures are required during that last year of life when local tumor growth or metastases require treatment. Additionally, Hugosson et al, reported that men who died of prostate cancer had more than 50% higher costs compared with men with prostate cancer who died of other causes. 7 Information regarding medication usage, especially outpatient use, ie pain or hormonal ablation, admittedly was incomplete in this study. Because of this, some assumptions had to be made but were always done so in an underestimation. The costs of other medications contributed little to the overall costs and were omitted. In addition, the costs of Hospice and nursing home care could not be assessed. In studies by Beemsterboer et al these costs averaged 7 -8% of total costs. 8 The average total cost of terminal care in the last year of life in this series was $24 660. This amount is higher than the $11 182 expended over 2 y of terminal care assessed by Beemsterboer et al, in their 1999 article. 8 However, both that report and the current study point out that all charges are impossible to calculate completely and will also vary on location in the country. We agree with their assertion that if screening proves to be effective and prevents disability and death due to disease then cost estimates can be used to calculate savings proportionate to the number of men prevented from dying of prostate cancer. This reduction in cost will partially balance the costs of screening, diagnosis and early treatment.
We further agree that not all men with localized disease require therapy. A significant proportion of men do have intercurrent illnesses from which they will succumb before the impact of their prostate cancer becomes manifest. However they are in the minority for those patients with significant tumors. Even for those patients in their sixties with moderately differentiated tumors (Gleason's score 5, 6, 7) the risk of ultimately dying of localized disease that was initially observed is over 60%. 7 The majority of men with metastatic disease will die and will require intensive palliation during their terminal year. Until the natural history of localized disease for the individual patient can be predicted it must be assumed that his disease is potentially lethal in the absence of a significant competing co-morbidity. Thus, early treatment may be of benefit as regards to quality of life, physiologically, psychologically, and perhaps, economically.
Conclusion
Patients with prostate cancer treated with a non-curative intent consume a large number of health care resources annually. Although the costs and prices we calculated are crude assessments, they are however underestimates of the costs incurred by these patients. In addition, as previously stated some items are immeasurable such as the psychological costs.
Overall, in our series, the average prostate cancer patient dying of metastatic disease spent 19 days hospitalized, received at least two palliative procedures, and 5.4 transfusions. We attempted to calculate the cost of these interventions finding that the average cost for the last year of life was over $24 000. By present estimates, about 86 men die each day in the USA due to cancer of the prostate. Using our cost assessment and the most recent estimates of prostate cancer mortality this would translate into over three quarters of a billion dollars spent annually in the palliative treatment of end-stage prostate cancer. We must, however, re-emphasize that this is, at best, an underestimation. This series, and the work of others before it, suggests that if a patient diagnosed with localized disease lives long enough to develop metastasis, and then succumbs due to it, intervention at the outset may have been the more economically prudent course.
